StockData
Halozyme Therapeutics, Inc. logo

Halozyme Therapeutics, Inc. (HALO) stock

HALONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 13/3037% above fair value
$95.80−0.17 (-0.18%)

Close on Nov 18, 2026Market cap $10.87BP/E 28.3Yield –

Halozyme Therapeutics market cap

Market capitalization is the share price multiplied by the number of shares outstanding.

Halozyme Therapeutics's market cap was $11.60B on Nov 11, 2026, against $8.39B a year earlier. Over the last 5 years it ranged from $4.27B to $14.93B, with a median of $6.66B.

Market Cap at the end of each year

PeriodPeriod endValueChange
2026Nov 11, 2026$11.60B+46.6%
2025Dec 31, 2025$7.91B+30.1%
2024Dec 31, 2024$6.08B+24.6%
2023Dec 29, 2023$4.88B-36.5%
2022Dec 30, 2022$7.69B+35.7%
2021Dec 31, 2021$5.67B-2.0%
2020Dec 31, 2020$5.78B+122.7%
2019Dec 31, 2019$2.60B+22.8%
2018Dec 31, 2018$2.11B-26.7%
2017Dec 29, 2017$2.88B+125.4%
2016Dec 30, 2016$1.28B-42.2%
2015Dec 31, 2015$2.21B+82.8%
2014Dec 31, 2014$1.21B-29.1%
2013Dec 31, 2013$1.71B+126.0%
2012Dec 31, 2012$756.17M-23.3%
2011Dec 30, 2011$985.69M–

More Halozyme Therapeutics figures

See a number that looks wrong?